{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:35:41Z","timestamp":1793745341095,"version":"4.6.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012353","name":"German Cancer Consortium","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012353","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013865","name":"Stiftung Charit\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"publisher","award":["2017.048.2"],"award-info":[{"award-number":["2017.048.2"]}],"id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021372","name":"HW & J Hector Stiftung","doi-asserted-by":"publisher","award":["M2408"],"award-info":[{"award-number":["M2408"]}],"id":[{"id":"10.13039\/501100021372","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRU5002"],"award-info":[{"award-number":["CRU5002"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["529255113"],"award-info":[{"award-number":["529255113"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["494535244"],"award-info":[{"award-number":["494535244"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["533770413"],"award-info":[{"award-number":["533770413"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EXC 3118\/1"],"award-info":[{"award-number":["EXC 3118\/1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KE 222\/11"],"award-info":[{"award-number":["KE 222\/11"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["58460329"],"award-info":[{"award-number":["58460329"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["WI 6148\/1"],"award-info":[{"award-number":["WI 6148\/1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017268","name":"Berlin Institute of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Stiftung Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70115444"],"award-info":[{"award-number":["70115444"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Stiftung Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["700111944"],"award-info":[{"award-number":["700111944"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Stiftung Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70114724"],"award-info":[{"award-number":["70114724"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Stiftung Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70116097"],"award-info":[{"award-number":["70116097"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1053\/j.gastro.2025.08.018","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T09:32:43Z","timestamp":1761557563000},"page":"315-329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Targeting Mutual Dependence of Phosphatidylinositol-3-Kinase \u03b1\/\u03b4 and Small Ubiquitin-Like Modifier Signaling in Pancreatic Cancer"],"prefix":"10.1053","volume":"170","author":[{"given":"Hazal","family":"K\u00f6se","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Schneeweis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Putze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constanza Tapia","family":"Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ferreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Deidda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Herzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juraj","family":"Jakubik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leoni","family":"Moldaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jovan","family":"Todorovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Tr\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanbing","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta M.","family":"Demel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Hessmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieluise","family":"Kirchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Rhein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Tatarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ghadimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Saur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Kappert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Mertins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8340-0872","authenticated-orcid":false,"given":"Matthias","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2025.08.018_bib1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/17474124.2024.2322648","article-title":"Next-generation therapies for pancreatic cancer","volume":"18","author":"Buckley","year":"2024","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.08.018_bib2","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: advances and challenges","volume":"186","author":"Halbrook","year":"2023","journal-title":"Cell"},{"key":"10.1053\/j.gastro.2025.08.018_bib3","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","article-title":"Targeting KRAS in cancer","volume":"30","author":"Singhal","year":"2024","journal-title":"Nat Med"},{"key":"10.1053\/j.gastro.2025.08.018_bib4","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","article-title":"Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer","volume":"14","author":"Dilly","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1053\/j.gastro.2025.08.018_bib5","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/nm.3646","article-title":"A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer","volume":"20","author":"Schonhuber","year":"2014","journal-title":"Nat Med"},{"key":"10.1053\/j.gastro.2025.08.018_bib6","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ccr.2013.01.023","article-title":"Selective requirement of PI3K\/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer","volume":"23","author":"Eser","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1053\/j.gastro.2025.08.018_bib7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12943-024-02072-1","article-title":"Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions","volume":"23","author":"Li","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1053\/j.gastro.2025.08.018_bib8","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/gutjnl-2018-316822","article-title":"Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine","volume":"68","author":"Conway","year":"2019","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2025.08.018_bib9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1053\/j.gastro.2025.08.018_bib10","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andre","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.08.018_bib11","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1158\/1078-0432.CCR-17-0725","article-title":"A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors","volume":"23","author":"Mateo","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2025.08.018_bib12","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1158\/1078-0432.CCR-22-3313","article-title":"Eganelisib, a first-in-class PI3Kgamma Inhibitor, in patients with advanced solid tumors: results of the phase 1\/1b MARIO-1 Trial","volume":"29","author":"Hong","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2025.08.018_bib13","doi-asserted-by":"crossref","first-page":"e1604","DOI":"10.1634\/theoncologist.2020-0321","article-title":"A phase Ib study of single-agent idelalisib followed by idelalisib in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma","volume":"25","author":"Borazanci","year":"2020","journal-title":"Oncologist"},{"key":"10.1053\/j.gastro.2025.08.018_bib14","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1021\/acsmedchemlett.9b00334","article-title":"INCB050465 (parsaclisib), a novel next-generation inhibitor of phosphoinositide 3-kinase delta (PI3Kdelta)","volume":"10","author":"Yue","year":"2019","journal-title":"ACS Med Chem Lett"},{"key":"10.1053\/j.gastro.2025.08.018_bib15","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrc.2016.143","article-title":"SUMO and the robustness of cancer","volume":"17","author":"Seeler","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.gastro.2025.08.018_bib16","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1136\/gutjnl-2018-317856","article-title":"SUMO pathway inhibition targets an aggressive pancreatic cancer subtype","volume":"69","author":"Biederstadt","year":"2020","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2025.08.018_bib17","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1136\/gutjnl-2021-324834","article-title":"Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model","volume":"71","author":"Kumar","year":"2022","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2025.08.018_bib18","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/1878-0261.13725","article-title":"KRAS(G) (12C)-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening","volume":"19","author":"Tapia Contreras","year":"2025","journal-title":"Mol Oncol"},{"key":"10.1053\/j.gastro.2025.08.018_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.108711","article-title":"In situ modeling of acquired resistance to RTK\/RAS-pathway-targeted therapies","volume":"27","author":"Sealover","year":"2024","journal-title":"iScience"},{"key":"10.1053\/j.gastro.2025.08.018_bib20","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41419-019-1591-4","article-title":"The PAX6-ZEB2 axis promotes metastasis and cisplatin resistance in non-small cell lung cancer through PI3K\/AKT signaling","volume":"10","author":"Wu","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1053\/j.gastro.2025.08.018_bib21","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.3390\/ijms20194917","article-title":"The antitumor effect of lipophilic bisphosphonate BPH1222 in melanoma models: the role of the PI3K\/Akt pathway and the small G protein Rheb","volume":"20","author":"Rittler","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.gastro.2025.08.018_bib22","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1159\/000490142","article-title":"The critical role of PTEN\/PI3K\/AKT signaling pathway in shikonin-induced apoptosis and proliferation inhibition of chronic myeloid leukemia","volume":"47","author":"Chen","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"10.1053\/j.gastro.2025.08.018_bib23","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.1158\/1078-0432.CCR-24-1164","article-title":"Clinical and genomic features of classical and basal transcriptional subtypes in pancreatic cancer","volume":"30","author":"Singh","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2025.08.018_bib24","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nature25459","article-title":"Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes","volume":"554","author":"Mueller","year":"2018","journal-title":"Nature"},{"key":"10.1053\/j.gastro.2025.08.018_bib25","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/s43018-023-00628-6","article-title":"Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC","volume":"4","author":"Zhou","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1053\/j.gastro.2025.08.018_bib26","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/s41467-017-00942-5","article-title":"Survival of pancreatic cancer cells lacking KRAS function","volume":"8","author":"Muzumdar","year":"2017","journal-title":"Nat Commun"},{"key":"10.1053\/j.gastro.2025.08.018_bib27","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1158\/1535-7163.MCT-19-1131","article-title":"A genome-scale CRISPR screen identifies the ERBB and UBA2 signaling networks as key determinants of response to PI3K inhibition in pancreatic cancer","volume":"19","author":"Milton","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1053\/j.gastro.2025.08.018_bib28","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.211904","article-title":"SUMO-specific proteases and isopeptidases of the SENP family at a glance","volume":"131","author":"Kunz","year":"2018","journal-title":"J Cell Sci"},{"key":"10.1053\/j.gastro.2025.08.018_bib29","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1021\/acs.jmedchem.0c01491","article-title":"Discovery of TAK-981, a first-in-class inhibitor of SUMO-activating enzyme for the treatment of cancer","volume":"64","author":"Langston","year":"2021","journal-title":"J Med Chem"},{"key":"10.1053\/j.gastro.2025.08.018_bib30","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1021\/jm800295d","article-title":"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer","volume":"51","author":"Folkes","year":"2008","journal-title":"J Med Chem"},{"key":"10.1053\/j.gastro.2025.08.018_bib31","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1158\/1535-7163.MCT-12-0993-T","article-title":"BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110alpha and p110delta activities in tumor cell lines and xenograft models","volume":"12","author":"Liu","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1053\/j.gastro.2025.08.018_bib32","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S1470-2045(21)00145-5","article-title":"Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Matasar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.gastro.2025.08.018_bib33","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1158\/1535-7163.MCT-19-0466","article-title":"On-target pharmacodynamic activity of the PI3K inhibitor copanlisib in paired biopsies from patients with malignant lymphoma and advanced solid tumors","volume":"19","author":"Morschhauser","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1053\/j.gastro.2025.08.018_bib34","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1078-0432.CCR-14-2034","article-title":"Idelalisib: first-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma","volume":"21","author":"Yang","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2025.08.018_bib35","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/mc.20569","article-title":"PI3K signaling maintains c-myc expression to regulate transcription of E2F1 in pancreatic cancer cells","volume":"48","author":"Schild","year":"2009","journal-title":"Mol Carcinog"},{"key":"10.1053\/j.gastro.2025.08.018_bib36","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41416-020-01119-6","article-title":"The SUMO pathway in pancreatic cancer: insights and inhibition","volume":"124","author":"Schneeweis","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1053\/j.gastro.2025.08.018_bib37","doi-asserted-by":"crossref","DOI":"10.1172\/JCI152383","article-title":"Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer","volume":"132","author":"Demel","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1053\/j.gastro.2025.08.018_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba7791","article-title":"A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models","volume":"13","author":"Lightcap","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.gastro.2025.08.018_bib39","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/s41416-024-02715-6","article-title":"Clinical landscape of macrophage-reprogramming cancer immunotherapies","volume":"131","author":"Rannikko","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1053\/j.gastro.2025.08.018_bib40","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1007\/s00204-025-04036-w","article-title":"A silence catalyst: CCL5-mediated intercellular communication in cancer","volume":"99","author":"Hu","year":"2025","journal-title":"Arch Toxicol"},{"key":"10.1053\/j.gastro.2025.08.018_bib41","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013502","article-title":"Pancreatic cancer intrinsic PI3Kalpha activity accelerates metastasis and rewires macrophage component","volume":"13","author":"Thibault","year":"2021","journal-title":"EMBO Mol Med"},{"key":"10.1053\/j.gastro.2025.08.018_bib42","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.cell.2007.03.051","article-title":"Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice","volume":"129","author":"Gupta","year":"2007","journal-title":"Cell"},{"key":"10.1053\/j.gastro.2025.08.018_bib43","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1101\/gad.249409.114","article-title":"Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110alpha","volume":"28","author":"Baer","year":"2014","journal-title":"Genes Dev"},{"key":"10.1053\/j.gastro.2025.08.018_bib44","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1053\/j.gastro.2014.08.032","article-title":"PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice","volume":"147","author":"Wu","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.08.018_bib45","doi-asserted-by":"crossref","first-page":"4928","DOI":"10.1158\/1078-0432.CCR-10-1210","article-title":"Key role of phosphoinositide 3-kinase class IB in pancreatic cancer","volume":"16","author":"Edling","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2025.08.018_bib46","doi-asserted-by":"crossref","first-page":"14724","DOI":"10.1073\/pnas.1813012116","article-title":"p110gamma deficiency protects against pancreatic carcinogenesis yet predisposes to diet-induced hepatotoxicity","volume":"116","author":"Torres","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.gastro.2025.08.018_bib47","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1158\/2159-8290.CD-15-1346","article-title":"Macrophage PI3Kgamma drives pancreatic ductal adenocarcinoma progression","volume":"6","author":"Kaneda","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1053\/j.gastro.2025.08.018_bib48","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1158\/2159-8290.CD-19-1006","article-title":"Atypical KRAS(G12R) mutant is impaired in PI3K signaling and macropinocytosis in pancreatic cancer","volume":"10","author":"Hobbs","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1053\/j.gastro.2025.08.018_bib49","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1158\/1535-7163.MCT-20-0981","article-title":"Phosphoproteomics identifies PI3K inhibitor-selective adaptive responses in pancreatic cancer cell therapy and resistance","volume":"20","author":"Cintas","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1053\/j.gastro.2025.08.018_bib50","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.cell.2012.10.021","article-title":"Protein group modification and synergy in the SUMO pathway as exemplified in DNA repair","volume":"151","author":"Psakhye","year":"2012","journal-title":"Cell"},{"key":"10.1053\/j.gastro.2025.08.018_bib51","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13008-015-0010-1","article-title":"Sumo and the cellular stress response","volume":"10","author":"Enserink","year":"2015","journal-title":"Cell Div"},{"key":"10.1053\/j.gastro.2025.08.018_bib52","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.210050","article-title":"SUMOylation modification-mediated cell death","volume":"11","author":"Sheng","year":"2021","journal-title":"Open Biol"},{"key":"10.1053\/j.gastro.2025.08.018_bib53","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1182\/bloodadvances.2024013236","article-title":"CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma","volume":"8","author":"Zinzani","year":"2024","journal-title":"Blood Adv"},{"key":"10.1053\/j.gastro.2025.08.018_bib54","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1200\/JCO.21.01648","article-title":"Phase II study of copanlisib in patients with tumors with PIK3CA mutations: results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F","volume":"40","author":"Damodaran","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.gastro.2025.08.018_bib55","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/imm.13441","article-title":"Double-negative T cells: setting the stage for disease control or progression","volume":"165","author":"Velikkakam","year":"2022","journal-title":"Immunology"},{"key":"10.1053\/j.gastro.2025.08.018_bib56","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1002\/1878-0261.12851","article-title":"Targeting immunogenic cell death in cancer","volume":"14","author":"Ahmed","year":"2020","journal-title":"Mol Oncol"},{"key":"10.1053\/j.gastro.2025.08.018_bib57","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1158\/1535-7163.MCT-23-0572","article-title":"Inhibition of SUMOylation induces adaptive antitumor immunity against pancreatic cancer through multiple effects on the tumor microenviro nmol\/Lent","volume":"23","author":"Erdem","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"10.1053\/j.gastro.2025.08.018_bib58","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1172\/JCI123540","article-title":"Tumor-intrinsic PIK3CA represses tumor immunogenecity in a model of pancreatic cancer","volume":"129","author":"Sivaram","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1053\/j.gastro.2025.08.018_bib59","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s40425-018-0457-0","article-title":"PI3Kalpha\/delta inhibition promotes anti-tumor immunity through direct enhancement of effector CD8(+) T-cell activity","volume":"6","author":"Carnevalli","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1053\/j.gastro.2025.08.018_bib60","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508525059037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508525059037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T13:56:00Z","timestamp":1779717360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508525059037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0016508525059037"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2025.08.018","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting Mutual Dependence of Phosphatidylinositol-3-Kinase \u03b1\/\u03b4 and Small Ubiquitin-Like Modifier Signaling in Pancreatic Cancer","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2025.08.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}